(Q46804778)

English

Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

bioavailability

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Gilbert Lefèvre

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

Françoise Pommier

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

Greg Sedek

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

Mark Allison

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

Hsun-Lun Aaron Huang

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

Beate Kiese

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

Yu-Yun Ho

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

Silke Appel-Dingemanse

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

publication date

1 February 2008

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

48

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

246-252

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

A new and rapid colorimetric determination of acetylcholinesterase activity

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Rivastigmine. A review of its use in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

A review of rivastigmine: a reversible cholinesterase inhibitor

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Absorption of rivastigmine from different regions of the gastrointestinal tract in humans

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270007312154

21 January 2018

Identifiers

10.1177/0091270007312154

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18199897

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46804778&oldid=2143778503"